Aroylguanidine-based factor Xa inhibitors: The discovery of BMS-344577

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 24, 2009, Pages 6882-6889

  Shi, Yan ^a   Li, Chi ^a   O'Connor, Stephen P ^a   Zhang, Jing ^a   Shi, Mengxiao ^a   Bisaha, Sharon N ^a   Wang, Ying ^a   Sitkoff, Doree ^a   Pudzianowski, Andrew T ^a   Huang, Christine ^a   Klei, Herbert E ^a   Kish, Kevin ^a   Yanchunas Jr , Joseph ^a   Liu, Eddie C K ^a   Hartl, Karen S ^a   Seiler, Steve M ^a   Steinbacher, Thomas E ^a   Schumacher, William A ^a   Atwal, Karnail S ^a   Stein, Philip D ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Aroylguanidine; CYP3A4 inhibition; Factor Xa inhibitor; Orally active

Indexed keywords

6 (DIMETHYLCARBAMOYL) NICOTINOYL GUANIDINE; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 7A; BMS 344577; CYTOCHROME P450 3A4; GUANIDINE DERIVATIVE; LACTAM DERIVATIVE; PLASMIN; PLASMINOGEN ACTIVATOR; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN; TRYPTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CAROTID ARTERY FLOW; CAVA VEIN; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; IC 50; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTHROMBIN TIME; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TIME TO MAXIMUM PLASMA CONCENTRATION; VEIN THROMBOSIS; X RAY CRYSTALLOGRAPHY;

ANTICOAGULANTS; CYTOCHROME P-450 CYP3A; DRUG DISCOVERY; FACTOR XA; GUANIDINES; HUMANS; INHIBITORY CONCENTRATION 50; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 71849107152     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.084     Document Type: Article

References (49)

1. Murray C.J.L., and Lopez A.D. Lancet 349 (1997) 1269
2. White R.H. Circulation 107 (2003) I4
3. Hirsh J. N. Eng. J. Med. 324 (1991) 1565
4. van A.H., Bode C., Darius H., Diehm C., Encke A., Gulba D.C., Haas S., Hacke W., Puhl W., Quante M., Riess H., Scharf R., Schellong S., Schror T., Schulte K.L., and Tebbe U. Clin. Appl. Thromb. Hemost. 7 (2001) 195
5. Weitz J.I. N. Eng. J. Med. 337 (1997) 688
6. Lassen M.R., and Laux V. Vasc. Health Risk Manag. 4 (2008) 1373
7. Harenberg J. Semin. Thromb. Hemost. 34 (2008) 779
8. Agnelli G., and Becattini C. Semin. Thromb. Hemost. 32 (2006) 793
9. Haas S. J. Thromb. Thrombolysis 25 (2008) 52
10. Shirk R.A., and Vlasuk G.P. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1895
11. For recent reviews on FXa inhibitors, see:. Kunitada S., Nagahara T., and Hara T. Handbook Exp. Pharmacol. (1998) 397
12. Vacca J.P. Annu. Rep. Med. Chem. 33 (1998) 81
13. Zhu B.-Y., and Scarborough R.M. Curr. Opin. Cardiov, Pulmon, Ren. Invest. Drugs 1 (1999) 63
14. Ewing W.R., Pauls H.W., and Spada A.P. Drugs Future 24 (1999) 771
15. Fevig J.M., and Wexler R.R. Annu. Rep. Med. Chem. 34 (1999) 81
16. Betz A. Exp. Opin. Ther. Patents 11 (2001) 1007
17. Walenga J.M., Jeske W.P., Hoppensteadt D., and Fareed J. Curr. Opin. Invest. Drugs 4 (2003) 272
18. Gould W.R., and Leadley R.J. Curr. Pharm. Des. 9 (2003) 2337
19. Quan M.L., and Smallheer J.M. Curr. Opin. Drug Discovery Dev. 7 (2004) 460
20. Roehrig S., Straub A., Pohlmann J., Lampe T., Pernerstorfer J., Schlemmer K.-H., Reinemer P., and Perzborn E. J. Med. Chem. 48 (2005) 5900
21. Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., Misselwitz F., and Kaelebo P. J. Thromb. Haemost. 4 (2006) 121
22. Kubitza D., Becka M., Wensing G., Voith B., and Zuehlsdorf M. Eur. J. Clin. Pharmacol. 61 (2005) 873
23. Turpie A.G.G., Fisher W.D., Bauer K.A., Kwong L.M., Irwin M.W., Kalebo P., Misselwitz F., and Gent M. J. Thromb. Haemost. 3 (2005) 2479
24. Pinto D.J.P., Orwat M.J., Koch S., Rossi K.A., Alexander R.S., Smallwood A., Wong P.C., Rendina A.R., Luettgen J.M., Knabb R.M., He K., Xin B., Wexler R.R., and Lam P.Y.S. J. Med. Chem. 50 (2007) 5339
25. Wong P.C., Crain E.J., Xin B., Wexler R.R., Lam P.Y., Pinto D.J., Luettgen J.M., and Knabb R.M. J. Thromb. Haemost. 6 (2008) 820
26. Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., and Deitchman D. J. Thromb. Haemost. 5 (2007) 2368
27. APPRAISE Steering Committee and Investigators. Circulation 119 (2009) 2877
28. Quan M.L., Lam P.Y.S., Han Q., Pinto D.J.P., He M.Y., Li R., Ellis C.D., Clark C.G., Teleha C.A., Sun J.-H., Alexander R.S., Bai S., Luettgen J.M., Knabb R.M., Wong P.C., and Wexler R.R. J. Med. Chem. 48 (2005) 1729
29. Agnelli G., Haas S.K., Krueger K.A., Bedding A.W., and Brandt J.T. ASH Annu. Meeting Abstracts 106 (2005) 278
30. Hampton T. J. Am. Med. Assoc. (JAMA) 295 (2006) 743
31. Liebeschuetz J.W., Jones S.D., Wiley M.E., and Young S.C. Struct.-Based Drug Discovery (2006) 173
32. Iwatsuki Y., Shigenaga T., Moritani Y., Suzuki M., Ishihara T., Hirayama F., and Kawasaki T. Blood 108 (2006) Abst 911
33. Eriksson B.I., Turpie A.G.G., Lassen M.L., Prins M.H., Agnelli G., Kalebo P., Gaillard M.L., and Meems L. J. Thromb. Haemost. 5 (2007) 1660
34. Haginoya N., Kobayashi S., Komoriya S., Yoshino T., Suzuki M., Shimada T., Watanabe K., Hirokawa Y., Furugori T., and Nagahara T. J. Med. Chem. 47 (2004) 5167
35. Zafar M.U., Gaztanga J., Velez M., Vorchheimer D., Choi B., Viles-Gonzalez J., Moreno P., Fuster V., and Badimon J. J. Am. Coll. Cardiol. 47 (2006) Abst 288A
36. Bisacchi G.S., Stein P.D., Gougoutas J.Z., Hartl K.S., Lawrence R.M., Liu E.C., Pudzianowski A.T., Schumacher W.A., Sitkoff D., Steinbacher T.E., Sutton J., Zhang Z., and Seiler S.M. Lett. Drug Des. Discovery 2 (2005) 625
37. Shi Y., Zhang J., Stein P.D., Shi M., O'Connor S.P., Bisaha S.N., Li C., Atwal K.S., Bisacchi G.S., Sitkoff D., Pudzianowski A.T., Liu E.C., Hartl K.S., Seiler S.M., Youssef S., Steinbacher T.E., Schumacher W.A., Rendina A.R., Bozarth J.M., Peterson T.L., Zhang G., and Zahler R. Bioorg. Med. Chem. Lett. 15 (2005) 5453
38. Shi, Y.; Zhang, J.; Shi, M.; O'Connor, S. P.; Bisaha, S. N.; Li, C.; Sitkoff, D.; Pudzianowski, A. T.; Huang, C.; Chong, S.; Klei, H.; Kish, K.; Yanchunas, J.; Liu, E. C.-K.; Hartl, K. S.; Seiler, S. M.; Steinbacher, T. E.; Schumacher, W. A.; Atwal, K. S.; Stein, P. D. Bioorg. Med. Chem. Lett. 2009, doi:10.1016/j.bmcl.2009.06.014.
39. 50 (12 nM), probably due to its high plasma protein bounding value (98.7%) in human plasma. See Ref. 14.
40. For detailed assay methods, see:. Shi Y., Sitkoff D., Zhang J., Klei H.E., Kish K., Liu E.C.-K., Hartl K.S., Seiler S.M., Chang M., Huang C., Youssef S., Steinbacher T.E., Schumacher W.A., Grazier N., Pudzianowski A., Apedo A., Discenza L., Yanchunas Jr. J., Stein P.D., and Atwal K.S. J. Med. Chem. 51 (2008) 7541
41. O'Connor S.P., Atwal K.S., Li C., Liu E.C., Seiler S.M., Shi M., Shi Y., Stein P.D., and Wang Y. Bioorg. Med. Chem. Lett. 18 (2008) 4696
42. The X-ray crystal structure coordinates of 22 in human Factor Xa have been deposited in the Protein Data Bank (PDB code 3K9X).
43. Compound testing protocol: male Sprague-Dawley rats (320 to 390 g) were fasted overnight and then anesthetized with sodium pentobarbital (50 mg/kg, ip). The trachea was cannulated with PE-205 tubing to assure airway patency. Catheters (PE-50) were placed in the right carotid artery for blood withdrawal and in the left jugular vein for saline infusion (25 μL/min throughout the experiment) and for iv dosing of test compound. For intestinal delivery (id) of test compound, the small intestine was exposed via a midline laparotomy and a dosing catheter (PE-50) was inserted into the duodenum at the level of the bile duct. Animals received compound by id (30 mg/kg) and iv (10 mg/kg) route in a 1 mg/mL volume of vehicle (10% ethanol/90% PEG300) followed by a 0.3 mL saline flush. Arterial blood samples (0.5 mL) were withdrawn into 3.8% Na-citrate (1/10; v/v) for ex vivo prothrombin time (PT) determination before (0 min control), and at 30, 60, 90 and 120 min after test compound dosing. The PT were was measured using a Amelung KC4A micro coagulation analyzer (Heinrich Amelung GmbH, Lemgo, Germany) and the standard procedure described for Dade Thromboplastin-C reagent (Baxter Healthcare Corp., Miami, FL).
44. 50 >200 μM.
45. Maron D.M., and Ames B.N. Mutat. Res. 113 (1983) 173
46. - channel (r), NE transporter (h), DA transporter (r), GABA transporter (r), choline transporter (r). For details regarding the specific receptors and experimental conditions see http://www.cerep.fr/Cerep/Users/pages/catalog/binding/catalog.asp.
47. 2 application. Aspirin was included at its top cyclooxygenase inhibition dose in the rat since it now represents the standard of care for secondary prevention of arterial thrombosis
48. Zhang J., and Shi Y. Tetrahedron Lett. 41 (2000) 8075
49. Zhang J., Shi Y., Stein P., Atwal K., and Li C. Tetrahedron Lett. 43 (2002) 57